133446-40-9

Basic information

• Product Name: methyl R,S-4-(1-bromoethyl)-benzoate
• Synonyms: methyl R,S-4-(1-bromoethyl)-benzoate
• CAS NO: 133446-40-9
• Molecular Weight: 243.1
• Mol File: 133446-40-9.mol
• Article Data: 20

Chemical Properties

• CAS DataBase Reference: methyl R,S-4-(1-bromoethyl)-benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl R,S-4-(1-bromoethyl)-benzoate(133446-40-9)
• EPA Substance Registry System: methyl R,S-4-(1-bromoethyl)-benzoate(133446-40-9)

Safety Data

• Hazardous Substances Data: 133446-40-9(Hazardous Substances Data)

Upstream product

• 3609-53-8 methyl 4-acetylbenzoate 
• 84851-56-9 methyl 4-(1-hydroxy ethyl)benzoate 
• 67-56-1 methanol 
• 113023-73-7 4-(1-bromoethyl)-benzoic acid 
• 7364-20-7 4-ethyl-benzoic acid methyl ester 
• 619-64-7 p-ethylbenzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 1184924-55-7 methyl 4-{1-[(tert-butoxycarbonyl)({2-chloro-5-[(2-methyl-2,3-dihydro-1H-indol-1-yl)carbamoyl]phenyl}sulphonyl)amino]ethyl}-benzoate 
• 1322084-83-2 4-[1-(3,4-dichloro-phenoxy)-ethyl]-benzoic acid methyl ester 
• 32223-88-4 4-(2-Ethoxycarbonyl-1,5-dimethyl-3-oxo-hexyl)-benzoic acid ethyl ester 
• 80051-07-6 4-carbomethoxy-α-methylbenzylamine 

Relevant articles and documents

SMARCA DEGRADERS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same for the modulation of one or more SWI/SNF-related matrix associated actin dependent regulator of chromatin subfamily A (SMARCA) and/or polybromo-1 (PB-1) protein via ubiqitination and/or degradation by compounds. The compounds are bifunctional molecules that link a cereblon-binding moiety to a ligand that binds SMARCA and/or PB1 proteins.

BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.